Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ConocoPhillips heads into September with the Street playing catch-up to a stock that has already done most of the work, as a wave of analyst upgrades meets a stock trading near its highest level of the year.
The analyst story is the week's clearest signal. The direction of travel has been overwhelmingly bullish. Morgan Stanley raised its target to $151 on August 19, maintaining Overweight. Argus lifted to $153. UBS moved to $153 from $143. Susquehanna pushed to $161. Wells Fargo's target sits at a notably bullish $189. Only Barclays bucked the trend, trimming slightly to $150 from $155 while holding Overweight. The mean target across the Street is $145, against a current price of $136.19 — still implying roughly 6.5% upside despite the 13% gain over the past month. The analyst recommendation differential ranks in the 98th percentile of the ORTEX universe, meaning the consensus skew toward buy ratings is more extreme than almost any other stock in coverage. One holdout: Truist sits at Hold with a $130 target that is already below the current price, a sign that at least one part of the Street thinks the rally has more than priced in the good news.
Short interest and the borrow market add nothing to worry about here. Bears remain in full retreat. Short interest held near 1.23% of the free float this week — essentially flat after the 16% weekly drop flagged in the prior note and down 28% over the past month from around 20 million shares to just over 15 million. That compression has stalled rather than accelerated, but there is no sign of fresh positioning. Borrow is near-free at 0.29%, and availability is entirely unconstrained — the lending pool is orders of magnitude larger than demand. The short score of 29.8 has drifted modestly lower through the week. This is not a stock where the lending market tells a story worth telling.
Options positioning is mildly constructive. The put/call ratio dropped to 0.77 on September 1, about three-quarters of a standard deviation below its 20-day mean of 0.81. That is a light tilt toward calls relative to recent norms — a contrast with the defensive posture flagged two weeks ago, when the PCR ran well above the mean. The 52-week range on the PCR runs from 0.66 to 1.17, so the current reading sits in the lower third — leaning bullish, but not at an extreme. Options traders are not hedging aggressively into September.
Peers have had a good week too, which matters for context. APA led the group with a 7% weekly gain. CVX added 5.6% and DVN 4.6%. COP's own 3.3% weekly move therefore looks like a mild underperform within the cohort — something to note given that COP has dramatically outpaced peers year-to-date, up roughly 45% against more modest gains across OXY, EOG, and XOM. The valuation picture reflects this outperformance: the PE ratio has nudged up to 13.2 over the past month and EV/EBITDA sits near 5.8 — not stretched by energy standards, but no longer cheap. The dividend score ranks at the 74th percentile, and the factor profile is clean across most dimensions.
The next earnings print is scheduled for November 5. Between now and then, the question is whether the stock can sustain a premium to targets set just two weeks ago, or whether the Street needs to move the goalposts again to justify the multiple — and whether oil prices cooperate long enough to give the new CEO, Jeffrey O'Brien, a clean first full quarter on the numbers.
See the live data behind this article on ORTEX.
Open COP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
